Just one short year ago I started this blog with the intentions of sharing my experiences with addiction, drugs, harm reduction and methadone. Has the time ever flown by...
Any intravenous drug user can attest to the horrible pain that is opiate withdrawal, and the often times extreme lengths that they will go to in order to avoid it. There are several different methods users employ in an attempt to minimize or stave off withdrawals when their drug of choice is for whatever reason unavailable, all of which generally come with some level of risk and the possibility of transmitting disease. However a new method that has emerged amongst intravenous drug users in areas of Kenya and Tanzania has taken the risk to a whole new level.
Relmada Therapeutics Inc., a company involved in the development of treatments for chronic pain, has announced today that Health Canada has accepted their clinical trial application for two studies designed to test the safety and patient tolerability of the drug D-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain.
By K. Lanktree
- Freelance Writer -
- Blog Mistress -
- Former IV Drug User -
- Methadone Patient -
- Lover of all things Harm Reduction -
Help keep 'Studio L' online by donating to help offset the costs! Thanks💋